-

Theraclion: Monthly Information on the Total Number of Voting Rights and Shares Comprising the Share Capital

Article 223-16 du Règlement Général de l’Autorité des marchés financiers

MALAKOFF, France--(BUSINESS WIRE)--Regulatory News:

Theraclion (Paris:ALTHE):

Listed on Euronext Growth Paris
PEA PME eligible
ISIN Code : FR0010120402
Website : www.theraclion.com

Voting rights :

Date

Total number of shares of Theraclion

Total number of theoretical voting rights of Theraclion (1)

Total number of real voting rights of Theraclion (2)

31/05/2026

73 123 311

89 143 355

87 584 876

(1) Theoretical voting rights are calculated on the basis of all shares to which voting rights are attached, including shares stripped of voting rights, in accordance with Article 223-11 of the AMF's General Regulation
(2) Actual voting rights correspond to the total number of voting rights exercisable at the Annual General Meeting. They are calculated on the basis of the total number of voting rights attached to the total number of shares less shares stripped of voting rights.

About Theraclion

Theraclion is a French MedTech company developing a non-invasive alternative to surgery through the innovative use of focused ultrasound.
High-Intensity Focused Ultrasound (HIFU) does not require incisions or an operating room, leaves no scars, and allows patients to resume normal activities immediately. HIFU concentrates therapeutic ultrasound on an internal focal point from outside the body.
Theraclion is developing Sonovein®, a robotic HIFU platform for varicose vein treatment, CE marked under the MDR (EU 2017/745), with the potential to replace millions of surgical procedures each year. To date, Sonovein® has been adopted by more than a dozen centers worldwide and used in over 4,000 procedures. In the U.S., Sonovein® is not yet available for sale.
Based in Malakoff (Paris), Theraclion’s team comprises around 35 people.

For more information, please visit www.theraclion.com and follow the LinkedIn account.
Theraclion is listed on Euronext Growth Paris Eligible for the PEA-PME scheme
Ticker: ALTHE - ISIN Code: FR0010120402 LEI: 9695007X7HA7A1GCYD29

Contacts

Theraclion
Martin Deterre
Chief Executive Officer
investors@theraclion.com

Theraclion

BOURSE:ALTHE

Release Versions

Contacts

Theraclion
Martin Deterre
Chief Executive Officer
investors@theraclion.com

More News From Theraclion

Theraclion Initiates Its Commercial Momentum in the First Half of 2026

MALAKOFF, France--(BUSINESS WIRE)--Regulatory News: THERACLION (ISIN: FR0010120402; Ticker: ALTHE), an innovative company developing Sonovein®, a robotic platform for non-invasive varicose vein therapy using High-Intensity Focused Ultrasound (HIFU), today reports on its progress during the first half of 2026. By the end of the first half of 2026, Theraclion's commercial acceleration is beginning to show clearly across every stage of the sales cycle. This momentum has been accompanied by signifi...

Theraclion: First Half 2026 Report on the Liquidity Contract With CRÉDIT INDUSTRIEL ET COMMERCIAL

MALAKOFF, France--(BUSINESS WIRE)--Regulatory News: Theraclion (Paris:ALTHE): Listing venue: Euronext Growth Paris PEA-PME eligible ISIN Code: FR0010120402 Website: www.theraclion.com Under the liquidity contract entrusted by THERACLION to CRÉDIT INDUSTRIEL ET COMMERCIAL, as of June 30, 2026, the following resources were held in the liquidity account: 26,499 shares €3,355.99 During the 1st half of 2026, a total of the following was traded: BUY 380,553 shares €234,517.84 1,030 transactions SELL...

Theraclion Strengthens Its Governance by Appointing Vincent Gardès as Chairman of Its Board of Directors

MALAKOFF, France--(BUSINESS WIRE)--Regulatory News: THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing Sonovein®, a robotic platform for non-invasive varicose vein therapy using High-Intensity Focused Ultrasound (HIFU), announces that its Board of Directors, which met on July 8, 2026, has appointed Mr. Vincent Gardès as Chairman of the Board of Directors, with immediate effect. A Director of Theraclion since the General Meeting of June 18, 2026, after having served...
Back to Newsroom